Fractional model for pharmacokinetics of high dose methotrexate in children with acute lymphoblastic leukaemia

被引:38
|
作者
Popovic, Jovan K. [1 ]
Spasic, Dragan T. [2 ]
Tosic, Jela [3 ]
Kolarovic, Jovanka L. [3 ]
Malti, Rachid [4 ]
Mitic, Igor M. [5 ]
Pilipovic, Stevan [6 ]
Atanackovic, Teodor M. [7 ]
机构
[1] Univ Novi Sad, Dept Pharmacol Toxicol & Clin Pharmacol, Fac Med, Novi Sad 21000, Serbia
[2] Univ Novi Sad, Inst Mech, Fac Tech Sci, Novi Sad 21000, Serbia
[3] Univ Novi Sad, Inst Children & Youth Hlth Care Vojvodina, Haematol & Oncol Ctr, Fac Med, Novi Sad 21000, Serbia
[4] Univ Bordeaux 1, IMS Lab, F-33405 Talence, France
[5] Univ Novi Sad, Clin Ctr Vojvodina, Dept Nephrol & Clin Immunol, Fac Med, Novi Sad 21000, Serbia
[6] Univ Novi Sad, Dept Math & Informat, Fac Sci & Math, Novi Sad 21000, Serbia
[7] State Univ Novi Pazar, Inst Mech, Fac Tech Sci, Novi Pazar, Serbia
关键词
Fractional model; Methotrexate pharmacokinetics; Children; Leukaemia; POPULATION PHARMACOKINETICS; CALCULUS; CANCER; PHARMACOLOGY; TOXICITY; INFUSION; TIME;
D O I
10.1016/j.cnsns.2014.08.014
中图分类号
O29 [应用数学];
学科分类号
070104 ;
摘要
The aim of this study is to promote a model based on the fractional differential calculus related to the pharmacokinetic individualization of high dose methotrexate treatment in children with acute lymphoblastic leukaemia, especially in high risk patients. We applied two-compartment fractionalmodel on 8 selected cases with the largest number (4-19) of measured concentrations, among 43 pediatric patients received 24-h methotrexate 2-5 g/m(2) infusions. The plasma concentrations were determined by fluorescence polarization immunoassay. Our mathematical procedure, designed by combining Post's and Newton's method, was coded in Mathematica 8.0 and performed on Fujicu Celsius M470-2 PC. Experimental data show that most of the measured values of methotrexate were in decreasing order. However, in certain treatments local maximums were detected. On the other hand, integer order compartmental models do not give values which fit well with the observed data. By the use of our model, we obtained better results, since it gives more accurate behavior of the transmission, as well as the local maximums which were recognized in methotrexate monitoring. It follows from our method that an additional test with a small methotrexate dose can be suggested for the fractional system parameter identification and the prediction of a possible pattern with a full dose in the case of high risk patients. A special feature of the fractional model is that it can also recognize and better fit an observed non-monotonic behavior. A newparameter determination procedure can be successfully used. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:451 / 471
页数:21
相关论文
共 50 条
  • [1] Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia
    Gao, Xuan
    Qian, Xiao-Wen
    Zhu, Xiao-Hua
    Yu, Yi
    Miao, Hui
    Meng, Jian-Hua
    Jiang, Jun-Ye
    Wang, Hong-Sheng
    Zhai, Xiao-Wen
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [2] Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value ?
    Martelli, N.
    Mathieu, O.
    Margueritte, G.
    Bozonnat, M. C.
    Daures, J. -P.
    Bressolle, F.
    Hillaire-Buys, D.
    Peyriere, H.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2011, 36 (02) : 237 - 245
  • [3] Population pharmacokinetics of methotrexate in paediatric patients with acute lymphoblastic leukaemia and malignant lymphoma
    Zhan, Min
    Sun, Yiqi
    Zhou, Fang
    Wang, Honghong
    Chen, Zebin
    Yan, Lianzhen
    Li, Xingang
    XENOBIOTICA, 2022, 52 (03) : 265 - 273
  • [4] Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia
    Csordas, Katalin
    Hegyi, Marta
    Eipel, Oliver T.
    Muller, Judit
    Erdelyi, Daniel J.
    Kovacs, Gabor T.
    ANTI-CANCER DRUGS, 2013, 24 (02) : 189 - 197
  • [5] Pharmacokinetics of High-Dose Methotrexate in Infants Treated for Acute Lymphoblastic Leukemia
    Lonnerholm, Gudmar
    Valsecchi, Maria Grazia
    De Lorenzo, Paola
    Schrappe, Martin
    Hovi, Liisa
    Campbell, Myriam
    Mann, Georg
    Janka-Schaub, Gritta
    Li, Chi-Kong
    Stary, Jan
    Hann, Ian
    Pieters, Rob
    PEDIATRIC BLOOD & CANCER, 2009, 52 (05) : 596 - 601
  • [6] High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study
    Chen, Xiaoxiao
    Li, Jing
    Yu, Liting
    Hu, Wenting
    Cai, Jiaoyang
    Wang, Zhuo
    Chen, Changcheng
    Zhang, Xin
    Xie, Yangyang
    Wu, Kefei
    Mo, Yixiao
    Chen, Jihui
    Shen, Shuhong
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1354 - 1366
  • [7] Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma
    Barbara Faganel Kotnik
    Iztok Grabnar
    Petra Bohanec Grabar
    Vita Dolžan
    Janez Jazbec
    European Journal of Clinical Pharmacology, 2011, 67 : 993 - 1006
  • [8] Serum Methotrexate Level and Side Effects of High Dose Methotrexate Infusion in Pediatric Patients with Acute Lymphoblastic Leukaemia (ALL)
    Sajith, Manjusha
    Pawar, Atmaram
    Bafna, Vibha
    Bartakke, Sandip
    Subramanian, Kannan
    Vaidya, Neela
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2020, 36 (01) : 51 - 58
  • [9] Effect of Body Fat on Population Pharmacokinetics of High-Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia
    Orgel, Etan
    Nabais, Teresa
    Douglas, Christopher
    Mittelman, Steven D.
    Neely, Michael
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (06) : 755 - 762
  • [10] Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma
    Kotnik, Barbara Faganel
    Grabnar, Iztok
    Grabar, Petra Bohanec
    Dolzan, Vita
    Jazbec, Janez
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (10) : 993 - 1006